4 ms·

It would have taken many years to get the new technology approved, but we skipped a lot of that due to the pandemic. Now that we have lots of safety data it is

• kuhewa 5y ago
  Most of the years skipped though was red tape, bureaucratic slog, fundraising, clinical trial participant recruiting, and having a high enough absolute risk of infection in the population that it was not long at all to have a significant difference in effect between treatment arms. It probably helps that there's now a well develiped framework for mRNA and adenovirus vector vaccine approval, but ultimately any new antigen could certainly be unsafe and future candidates are going to require every bit as much testing and won't get most of the expeditiory benefits the first generation of COVID vaccines experienced.